Irritants - CS, CN, CNC, CA, CR, CNB, PS Medication
- Author: Paul P Rega, MD, FACEP; Chief Editor: Robert G Darling, MD, FACEP more...
Medication Summary
In general, only decontamination with water is necessary when a patient's skin has become grossly exposed. Bronchodilators, analgesics, and pulmonary support may be needed depending upon the severity of injury.
Bronchodilator
Class Summary
Use only for patients with evidence of significant bronchospasm after exposure.
Albuterol 0.5% (Proventil, Ventolin)
Beta-agonist for bronchospasm refractory to epinephrine. Relaxes bronchial smooth muscle by action on beta 2-receptors with little effect on cardiac muscle contractility.
Nonsteroidal anti-inflammatory agents (NSAIDs)
Class Summary
NSAIDs have analgesic, anti-inflammatory, and antipyretic activities. Their mechanism of action is not known, but they may inhibit cyclooxygenase activity and prostaglandin synthesis. Other mechanisms, such as inhibition of leukotriene synthesis, lysosomal enzyme release, lipoxygenase activity, neutrophil aggregation, and various cell-membrane functions, may exist as well.
Ibuprofen (Motrin, Ibuprin)
Acts as an analgesic, antipyretic, and anti-inflammatory agent.
Analgesics
Class Summary
Pain control is essential to quality patient care. Analgesics ensure patient comfort, promote pulmonary toilet, and have sedating properties, which are beneficial for patients who have sustained trauma or injuries.
Oxycodone/acetaminophen (Percocet, Roxicet, Roxilox)
Drug combination indicated for relief of moderate to severe pain.
Antibiotics
Class Summary
Therapy must cover all likely pathogens in the context of the clinical setting.
Gentamicin 0.3 % solution (Genoptic, Ocu-Mycin)
Indicated for corneal abrasions. Aminoglycoside antibiotic used for gram-negative bacterial coverage.
Erythromycin ophthalmic (E-Mycin)
Indicated for corneal abrasions and infections caused by susceptible strains of microorganisms and for prevention of corneal and conjunctival infections.
Hankin SM, Ramsay CN. Investigation of accidental secondary exposure to CS agent. Clin Toxicol (Phila). May 2007;45(4):409-11. [Medline].
Brone B, Peeters PJ, Marrannes R, et al. Tear gasses CN, CR, and CS are potent activators of the human TRPA1 receptor. Toxicol Appl Pharmacol. Sep 2008;231(2):150-6. [Medline].
Karagama YG, Newton JR, Newbegin CJ. Short-term and long-term physical effects of exposure to CS spray. J R Soc Med. Apr 2003;96(4):172-4. [Medline].
Watson K, Rycroft R. Unintended cutaneous reactions to CS spray. Contact Dermatitis. Jul 2005;53(1):9-13. [Medline].
Billmire DF, Vinocur C, Ginda M, Robinson NB, Panitch H, Friss H. Pepper-spray-induced respiratory failure treated with extracorporeal membrane oxygenation. Pediatrics. Nov 1996;98(5):961-3. [Medline].
Sam Shen. Riot-control agent attack. In: Ciottone GR, Anderson PD, Auf Der Heide E, Darling RG, Jacoby I, Noji E, Suner S, eds. Disaster Medicine. 3rd ed. Philadelphia, PA: Mosby/Elsevier; 2006:Chap 98, 593-595.
Centers for Disease Control and Prevention. Riot Control Agent Poisoning. CDC: Emergency Preparedness and Response. Available at http://emergency.cdc.gov/agent/riotcontrol/agentpoisoning.asp. Accessed March 7, 2009.
Viala B, Blomet J, Mathieu L, Hall AH. Prevention of CS "tear gas" eye and skin effects and active decontamination with Diphoterine: preliminary studies in 5 French Gendarmes. J Emerg Med. Jul 2005;29(1):5-8. [Medline].
Army, Marine Corps, Navy, Air Force. Military Chemical Compounds and Their Properties in Potential Military Chemical/Biological Agents and Compounds. January 2005. Available at www.mipt.org/pdf/Potential-Military-Chemical-Biological-Agents-Compounds.pdf. Accessed April 2, 2005.
Bentur Y, Gomez J. Incapacitating agents: BZ, calmative agents, and riot control agents. In: Keyes DC, Burstein JL, Schwartz RB, et al, eds. Medical Response to Terrorism, Preparedness and Clinical Practice. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.
Blain PG. Tear gases and irritant incapacitants. 1-chloroacetophenone, 2-chlorobenzylidene malononitrile and dibenz[b,f]-1,4-oxazepine. Toxicol Rev. 2003;22(2):103-10. [Medline].
CDC. Brief report: exposure to tear gas from a theft-deterrent device on a safe--Wisconsin, December 2003. MMWR Morb Mortal Wkly Rep. Mar 5 2004;53(8):176-7. [Medline].
CDC. Riot Control Agent Poisoning. Centers for Disease Control and Prevention Web site. Available at www.bt.cdc.gov/agent/riotcontrol/agentpoisoning.asp. Accessed May 12, 2004.
Chemical Casualty Care Division USAMRICD. Medical Response to Chemical Warfare and Terrorism. 3rd ed. i-iv, 73-79.
Compton JA. Tear agents. In: Military Chemical and Biological Agents. 1987:208-252.
Field Manual. Riot Control Agents. Treatment of Chemical Agent Casualties and Convention Military Chemical Injuries. Medical NBC Online Web site. Available at www.nbc-med.org/SiteContent/MedRef/OnlineRef/FieldManuals/fm8_285/Part_2/chapter7.htm. Accessed April 2, 2005.
Lillie SH, Hanlon E, Kelly JM, eds. Potential Military Chemical/Biological Agents and Compounds (FM3-11.9). 2005.
Nelson LS. Simple asphyxiants and pulmonary irritants. In: Goldfrank LR, Flomenbau NE, Lewin NA, eds. Goldfrank's Toxicologic Emergencies. Appleton & Lange; 1998:1523-1538.
Sidell FR. Riot control agents. In: Textbook of Military Medicine. Part 1. 1997:307-324.
USAMRICD. Riot Control Agents in Medical Management of Chemical Casualties Handbook. 3rd ed. USAMRICD. Available at: https://ccc.apgea.army.mil/sarea/products/handbooks/MMCC/mmccthirdeditionjul2000.pdf. July 2000.
Weir E. The health impact of crowd-control agents. CMAJ. Jun 26 2001;164(13):1889-90. [Medline].
Print
